GHK-Cu vs AHK-Cu (Copper AHK)

GHK-Cu and AHK-Cu (Copper AHK) are copper-binding tripeptides investigated for regenerative and dermatological research. GHK-Cu is endogenous, identified in human plasma and tissues, with levels declining with age—a factor linked to its study in skin aging and wound repair. AHK-Cu, by contrast, is a synthetic peptide designed to enhance copper delivery, particularly to dermal papilla cells. Their mechanisms differ: GHK-Cu modulates gene expression and collagen remodeling, while AHK-Cu focuses on follicular stimulation. This comparison evaluates their evidence bases, tradeoffs in research contexts, and selection criteria for specific applications.

GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide discovered by Dr. Loren Pickart in 1973. Plasma levels average 200 ng/mL at age 20, declining to ~80 ng/mL by age 60, suggesting a role in age-related tissue changes. Mechanistically, GHK-Cu binds copper ions to activate matrix metalloproteinases and enhance collagen synthesis, as shown in fibroblast cultures. It also modulates gene expression for antioxidant and anti-inflammatory pathways. Evidence is robust: decades of clinical use in wound healing and cosmetic formulations, supported by studies on skin firmness, elasticity, and fine lines. Molecular weight is ~340 g/mol (C14H24N6O4Cu). Research indicates it promotes angiogenesis and dermal regeneration, though most data derive from topical applications.

AHK-Cu is the copper-complexed form of the tripeptide alanyl-histidyl-lysine. Unlike GHK-Cu, it is synthetic and designed for targeted delivery to dermal papilla cells, which are critical for hair follicle cycling. Preclinical studies suggest that copper binding enhances its bioactivity, stimulating proliferation of dermal papilla cells in vitro and promoting hair growth in animal models. Evidence is less extensive than for GHK-Cu, with most research focusing on topical formulations for androgenetic alopecia. Key claims include superior hair growth stimulation compared to AHK alone, attributed to copper’s role in angiogenesis and cellular metabolism. However, human clinical data remain limited, and mechanisms beyond copper delivery are not fully elucidated.

Both peptides are studied for skin health, including wound healing and dermal regeneration. GHK-Cu is more extensively researched for anti-aging, collagen remodeling, and wound repair, with evidence spanning gene modulation and clinical outcomes. AHK-Cu is primarily investigated for hair growth, targeting dermal papilla cells in conditions like alopecia. Overlap exists in copper-mediated tissue repair, but GHK-Cu’s broader gene-regulatory effects contrast with AHK-Cu’s more specialized follicular focus. Researchers should consider these distinct applications when designing studies.

GHK-Cu has an excellent safety profile from decades of cosmetic and clinical use (PMID: 29986520). Topical forms are well-tolerated, with rare mild irritation in sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating sites reduces local irritation. AHK-Cu data are sparser, but potential risks include skin irritation at high concentrations and copper sensitivity in predisposed individuals. Both peptides require careful dosing in research protocols, with GHK-Cu’s broader safety record offering more confidence for long-term studies.